EPS for Magellan Health, Inc. (MGLN) Expected At $1.24

October 14, 2018 - By Darrin Black

Magellan Health, Inc. (NASDAQ:MGLN) LogoInvestors sentiment decreased to 0.92 in Q2 2018. Its down 0.11, from 1.03 in 2018Q1. It dropped, as 33 investors sold Magellan Health, Inc. shares while 73 reduced holdings. 27 funds opened positions while 70 raised stakes. 23.43 million shares or 1.11% more from 23.17 million shares in 2018Q1 were reported.
Assetmark reported 0% in Magellan Health, Inc. (NASDAQ:MGLN). Parametric Assocs has invested 0.01% of its portfolio in Magellan Health, Inc. (NASDAQ:MGLN). Swiss Retail Bank, Switzerland-based fund reported 41,400 shares. Los Angeles Cap Mgmt And Equity Research Incorporated reported 0.01% of its portfolio in Magellan Health, Inc. (NASDAQ:MGLN). Credit Suisse Ag owns 22,628 shares for 0% of their portfolio. Alpha Windward Ltd reported 5,520 shares. Eqis Cap Mngmt holds 5,638 shares or 0.03% of its portfolio. Putnam Invs Limited Com reported 5,200 shares. Hood River Lc stated it has 207,346 shares or 1.02% of all its holdings. 19,791 are held by Convergence Inv Prtn Lc. Massachusetts-based Martingale Asset Mgmt Ltd Partnership has invested 0.04% in Magellan Health, Inc. (NASDAQ:MGLN). Dimensional Fund Advsrs Limited Partnership reported 0.08% stake. Hillcrest Asset Mgmt Llc accumulated 1.76% or 98,361 shares. Petrus Tru Lta invested in 0.06% or 2,970 shares. Kennedy Mgmt has invested 0.1% in Magellan Health, Inc. (NASDAQ:MGLN).

Since May 1, 2018, it had 0 buys, and 3 sales for $3.67 million activity.

Analysts expect Magellan Health, Inc. (NASDAQ:MGLN) to report $1.24 EPS on November, 7.They anticipate $0.28 EPS change or 18.42 % from last quarter’s $1.52 EPS. MGLN’s profit would be $30.40M giving it 13.57 P/E if the $1.24 EPS is correct. After having $0.91 EPS previously, Magellan Health, Inc.’s analysts see 36.26 % EPS growth. The stock increased 0.63% or $0.42 during the last trading session, reaching $67.31. About 281,475 shares traded or 5.35% up from the average. Magellan Health, Inc. (NASDAQ:MGLN) has declined 10.31% since October 14, 2017 and is downtrending. It has underperformed by 25.93% the S&P500.

Magellan Health, Inc. (NASDAQ:MGLN) Ratings Coverage

Among 2 analysts covering Magellan Health (NASDAQ:MGLN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Magellan Health had 3 analyst reports since April 27, 2018 according to SRatingsIntel. The rating was maintained by Leerink Swann on Friday, April 27 with “Buy”. The stock of Magellan Health, Inc. (NASDAQ:MGLN) has “Outperform” rating given on Monday, July 30 by Raymond James. The company was upgraded on Tuesday, May 1 by Raymond James.

Magellan Health, Inc. engages in the healthcare management business in the United States. The company has market cap of $1.65 billion. The company's Healthcare segment engages in the management of behavioral healthcare services and employee assistance program services; management of other specialty areas, including diagnostic imaging and musculoskeletal management; and the integrated management of physical, behavioral, and pharmaceutical healthcare for special populations comprising individuals with serious mental illness, dual eligibles, long-term services and supports, and other populations with unique and often complex healthcare needs. It has a 15.14 P/E ratio. This segment provides its healthcare services through its comprehensive network of medical and behavioral health professionals, clinics, hospitals, and ancillary service providers.

More news for Magellan Health, Inc. (NASDAQ:MGLN) were recently published by: Nasdaq.com, which released: “New Research Coverage Highlights Magellan Health, AGNC Investment, EQT GP Holdings, LP, EnPro Industries …” on October 08, 2018. Investorplace.com‘s article titled: “5 Healthcare Stocks to Buy for Complete Portfolio Wellness” and published on October 10, 2018 is yet another important article.

Magellan Health, Inc. (NASDAQ:MGLN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News